50
Participants
Start Date
January 4, 2023
Primary Completion Date
June 30, 2026
Study Completion Date
June 30, 2026
Flecainide
Flecainide is mainly used for pharmacological conversion in patients with atrial tachyarrhythmias and to suppress ventricular arrhythmias in patients with structurally normal hearts.
Metoprolol
Metoprolol is a beta-blocker and class II antiarrhythmic drug considered standard care in most cardiac diseases predisposing to ventricular arrhythmias, including arrhythmic mitral valve prolapse.
RECRUITING
Oslo University Hospital Rikshospitalet, Oslo
The Research Council of Norway
OTHER
University of Oslo
OTHER
Oslo University Hospital
OTHER